MYLAN
VTRSNext catalyst
MR-107A-02
moderate-to-severe acute pain
Get an email about VTRS's next catalysts
Track MYLAN (VTRS) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 3 more upcoming events in our data (Phase 2 readout, Phase 3 readout).See the timeline
4 upcoming, 5 past
MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN) Phase 2 Est. Readout
Primary completion for MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN) trial (NCT07365904) in Contraception
SourceFDA PDUFA Date MR-107A-02 (fast-acting meloxicam)
For moderate-to-severe acute pain. Extracted from SEC filing: EX-99.1
SourcePhase 3 — VR-205
For Primary Immunoglobulin A Nephropathy. Viatris announced positive Phase 3 results for VR-205 in Japanese patients with primary immunoglobulin A nephropathy, with the drug meeting its primary endpoint and key secondary endpoints. The company targets Japanese New Drug Application submission by end of 2026.
SourceTransdermal system containing progestin Phase 3 Est. Readout
Primary completion for Transdermal system containing progestin trial (NCT06672016) in Female Contraception
SourceUpcoming FDA decisions
How VTRS's past catalysts played out
Market Overview
Stock performance and key metrics
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.
WebsiteMYL-1501D product using manufacture process VI
Diabetes Mellitus, Type 1
Amlodipine/atorvastatin single pill
Hypertension
MYL-1601D Product
Diabetes Mellitus, Type 1
venlafaxine ER (fixed dose)
Major Depressive Disorder
unfixed Latanoprost and Timolol
Glaucoma, Open Angle
LATANOPROST/TIMOLOL FIXED COMBINATION
Glaucoma, Primary Open Angle (POAG)
Revefenacin
Chronic Obstructive Pulmonary Disease, COPD
Econazole Nitrate
Tinea Pedis
cholecalciferol
Coronavirus
ziprasidone versus olanzapine, risperidone or quetiapine
Schizophrenia
fixed combination latanoprost-timolol
Ocular Hypertension
sildenafil citrate (UK-92,480)
Pulmonary Hypertension
celecoxib and ibuprofen SR
Pain, Postoperative
MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)
Asthma
Tramadol
Acute Pain
sildenafil
Sexual Dysfunctions, Psychological
Pregabalin Dose Level 1
Generalized Tonic Clonic Seizures
Pregabalin Dose Level 2
Partial Onset Seizures
Loxoprofen
Low Back Pain
Pregabalin add-on therapy
Epilepsy, Partial Seizures
FlexPen NovoLog®
Diabetes Mellitus, Type 1
pramipexole
Restless Legs Syndrome
tolterodine extended release capsule
Urinary Incontinence
Diclofenac sodium
Osteoarthritis, Knee
MR-107A-02
Acute Pain
Venlafaxine ER
Major Depressive Disorder
Venlafaxine XR
Anxiety
Xalacom
Glaucoma, Open Angle
Mylan's insulin glargine
Type 1 Diabetes
Lantus®
Type 2 Diabetes
MYL-1701P, a proposed biosimilar to Eylea
Diabetic Macular Edema
Ziprasidone
Schizophrenia
Pimecrolimus
Atopic Dermatitis
Transdermal system containing progestin
Female Contraception
MYL-1501D product using manufacture process V
Diabetes Mellitus, Type 1
Eletriptan HBr
Migraine Without Aura
Eplerenone
Heart Failure
Geodon (Ziprasidone)
Bipolar Disorder
Xalatan
Glaucoma, Open-Angle
Diphenhydramine citrate
Healthy
Indomethacin
Arthritis, Gouty
Atorvastatin calcium
Hypercholesterolemia
Ziprasidone Oral Capsule
Bipolar Mania
Intramuscular ziprasidone mesylate
Schizophrenia
Nebivolol
Hypertension
Timolol
Open Angle Glaucoma
Revefenacin in Inhalation
COPD
Amlodipine/Atorvastatin
Hypertension
Clozapine
Schizophrenia
Nebivolol and Atenolol
Hypertension
Estradiol Vaginal
Atrophic Vaginitis
Eletriptan
Migraine With or Without Aura
TD-4208
Chronic Obstructive Pulmonary Disease (COPD)
Lamotrigine
Epilepsy, Partial
Ziprasidone oral capsules
Bipolar Disorder
PhXA41
Open Angle Glaucoma
Tiotropium
Chronic Obstructive Pulmonary Disease (COPD)
MR-100A-01
Contraception
Nebivolol (NEB)
Hypertension
levetiracetam
Partial Seizures
i. Fixed combination of latanoprost and timolol
Ocular Hypertension
MYL-1401H
Breast Neoplasms
latanoprost
Glaucoma
Formoterol
Chronic Obstructive Pulmonary Disease (COPD)
Diclofenac SR
Ankylosing Spondylitis
pramipexol
Idiopathic Restless Legs Syndrome
Sumatriptan
Migraine With or Without Aura
MYL- 1401O
Breast Cancer
atazanavir boosted with ritonavir
HIV-1-infection
MYL-1701P
Diabetic Macular Edema
Gabapentin
Transient Insomnia
apomorphine HCl injection
Parkinson Disease
Amlodipine
Hypertension
iv sildenafil
Pulmonary Hypertension, Familial Persistent, of the Newborn
pregabalin
Neuralgia
celecoxib
Low Back Pain
MYL-1401A (Adalimumab)
Psoriasis
pregabalin (Lyrica)
Pain, Postoperative
Sildenafil citrate
Pulmonary Arterial Hypertension, Children
olanzapine
Schizophrenia
MR-107A-01
Pain
DTG orally plus TDF/3TC
HIV-associated Tuberculosis
Alprazolam
Dental Anxiety
Permethrin Foam
Scabies
MR-130A-01 Transdermal patch
Contraception
Cysteamine
HIV Infections
2HPZM
HIV-associated Tuberculosis
2HPM
HIV-associated Tuberculosis
sertraline/[S,S]-reboxetine
Depressive Disorder, Major
generic FDC of TDF/3TC/EFV
HIV
Revefenacin Inhalation Solution
COPD
Dolutegravir (DTG) orally (~12 hours apart) plus TDF/3TC
HIV-associated Tuberculosis
MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN)
Contraception
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
MYL-1501D product using manufacture process VI | Phase 3 | Diabetes Mellitus, Type 1 | - | - |
Amlodipine/atorvastatin single pill | Phase 3 | Hypertension | - | - |
MYL-1601D Product | Phase 3 | Diabetes Mellitus, Type 1 | - | - |
venlafaxine ER (fixed dose) | Phase 3 | Major Depressive Disorder | - | - |
unfixed Latanoprost and Timolol | Phase 3 | Glaucoma, Open Angle | - | - |
LATANOPROST/TIMOLOL FIXED COMBINATION | Phase 3 | Glaucoma, Primary Open Angle (POAG) | - | - |
Revefenacin | Phase 3 | Chronic Obstructive Pulmonary Disease, COPD | - | - |
Econazole Nitrate | Phase 3 | Tinea Pedis | - | - |
cholecalciferol | Phase 3 | Coronavirus | - | - |
ziprasidone versus olanzapine, risperidone or quetiapine | Phase 3 | Schizophrenia | - | - |
fixed combination latanoprost-timolol | Phase 3 | Ocular Hypertension | - | - |
sildenafil citrate (UK-92,480) | Phase 3 | Pulmonary Hypertension | - | - |
celecoxib and ibuprofen SR | Phase 3 | Pain, Postoperative | - | - |
MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate) | Phase 3 | Asthma | - | - |
Tramadol | Phase 3 | Acute Pain | - | - |
sildenafil | Phase 3 | Sexual Dysfunctions, Psychological | - | - |
Pregabalin Dose Level 1 | Phase 3 | Generalized Tonic Clonic Seizures | - | - |
Pregabalin Dose Level 2 | Phase 3 | Partial Onset Seizures | - | - |
Loxoprofen | Phase 3 | Low Back Pain | - | - |
Pregabalin add-on therapy | Phase 3 | Epilepsy, Partial Seizures | - | - |
FlexPen NovoLog® | Phase 3 | Diabetes Mellitus, Type 1 | - | - |
pramipexole | Phase 3 | Restless Legs Syndrome | - | - |
tolterodine extended release capsule | Phase 3 | Urinary Incontinence | - | - |
Diclofenac sodium | Phase 3 | Osteoarthritis, Knee | - | - |
MR-107A-02 | Phase 3 | Acute Pain | - | - |
Venlafaxine ER | Phase 3 | Major Depressive Disorder | - | - |
Venlafaxine XR | Phase 3 | Anxiety | - | - |
Xalacom | Phase 3 | Glaucoma, Open Angle | - | - |
Mylan's insulin glargine | Phase 3 | Type 1 Diabetes | - | - |
Lantus® | Phase 3 | Type 2 Diabetes | - | - |
MYL-1701P, a proposed biosimilar to Eylea | Phase 3 | Diabetic Macular Edema | - | - |
Ziprasidone | Phase 3 | Schizophrenia | - | - |
Pimecrolimus | Phase 3 | Atopic Dermatitis | - | - |
Transdermal system containing progestin | Phase 3 | Female Contraception | - | - |
MYL-1501D product using manufacture process V | Phase 3 | Diabetes Mellitus, Type 1 | - | - |
Eletriptan HBr | Phase 3 | Migraine Without Aura | - | - |
Eplerenone | Phase 3 | Heart Failure | - | - |
Geodon (Ziprasidone) | Phase 3 | Bipolar Disorder | - | - |
Xalatan | Phase 3 | Glaucoma, Open-Angle | - | - |
Diphenhydramine citrate | Phase 3 | Healthy | - | - |
Indomethacin | Phase 3 | Arthritis, Gouty | - | - |
Atorvastatin calcium | Phase 3 | Hypercholesterolemia | - | - |
Ziprasidone Oral Capsule | Phase 3 | Bipolar Mania | - | - |
Intramuscular ziprasidone mesylate | Phase 3 | Schizophrenia | - | - |
Nebivolol | Phase 3 | Hypertension | - | - |
Timolol | Phase 3 | Open Angle Glaucoma | - | - |
Revefenacin in Inhalation | Phase 3 | COPD | - | - |
Amlodipine/Atorvastatin | Phase 3 | Hypertension | - | - |
Clozapine | Phase 3 | Schizophrenia | - | - |
Nebivolol and Atenolol | Phase 3 | Hypertension | - | - |
Estradiol Vaginal | Phase 3 | Atrophic Vaginitis | - | - |
Eletriptan | Phase 3 | Migraine With or Without Aura | - | - |
TD-4208 | Phase 3 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
Lamotrigine | Phase 3 | Epilepsy, Partial | - | - |
Ziprasidone oral capsules | Phase 3 | Bipolar Disorder | - | - |
PhXA41 | Phase 3 | Open Angle Glaucoma | - | - |
Tiotropium | Phase 3 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
MR-100A-01 | Phase 3 | Contraception | - | - |
Nebivolol (NEB) | Phase 3 | Hypertension | - | - |
levetiracetam | Phase 3 | Partial Seizures | - | - |
i. Fixed combination of latanoprost and timolol | Phase 3 | Ocular Hypertension | - | - |
MYL-1401H | Phase 3 | Breast Neoplasms | - | - |
latanoprost | Phase 3 | Glaucoma | - | - |
Formoterol | Phase 3 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
Diclofenac SR | Phase 3 | Ankylosing Spondylitis | - | - |
pramipexol | Phase 3 | Idiopathic Restless Legs Syndrome | - | - |
Sumatriptan | Phase 3 | Migraine With or Without Aura | - | - |
MYL- 1401O | Phase 3 | Breast Cancer | - | - |
atazanavir boosted with ritonavir | Phase 3 | HIV-1-infection | - | - |
MYL-1701P | Phase 3 | Diabetic Macular Edema | - | - |
Gabapentin | Phase 3 | Transient Insomnia | - | - |
apomorphine HCl injection | Phase 3 | Parkinson Disease | - | - |
Amlodipine | Phase 3 | Hypertension | - | - |
iv sildenafil | Phase 3 | Pulmonary Hypertension, Familial Persistent, of the Newborn | - | - |
pregabalin | Phase 3 | Neuralgia | - | - |
celecoxib | Phase 3 | Low Back Pain | - | - |
MYL-1401A (Adalimumab) | Phase 3 | Psoriasis | - | - |
pregabalin (Lyrica) | Phase 3 | Pain, Postoperative | - | - |
Sildenafil citrate | Phase 3 | Pulmonary Arterial Hypertension, Children | - | - |
olanzapine | Phase 3 | Schizophrenia | - | - |
MR-107A-01 | Phase 2 | Pain | - | - |
DTG orally plus TDF/3TC | Phase 2 | HIV-associated Tuberculosis | - | - |
Alprazolam | Phase 2 | Dental Anxiety | - | - |
Permethrin Foam | Phase 2 | Scabies | - | - |
MR-130A-01 Transdermal patch | Phase 2 | Contraception | - | - |
Cysteamine | Phase 2 | HIV Infections | - | - |
2HPZM | Phase 2 | HIV-associated Tuberculosis | - | - |
2HPM | Phase 2 | HIV-associated Tuberculosis | - | - |
sertraline/[S,S]-reboxetine | Phase 2 | Depressive Disorder, Major | - | - |
generic FDC of TDF/3TC/EFV | Phase 2 | HIV | - | - |
Revefenacin Inhalation Solution | Phase 2 | COPD | - | - |
Dolutegravir (DTG) orally (~12 hours apart) plus TDF/3TC | Phase 2 | HIV-associated Tuberculosis | - | - |
MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN) | Phase 2 | Contraception | - | - |
presbyopia
3 drugs in this indication
pain management
1 drug in this indication
excessive daytime sleepiness related to obstructive sleep apnea syndrome and narcolepsy types 1 and 2
1 drug in this indication
presbyopia in adults
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in MYLAN's drug pipeline?→
CatalystAlert tracks 93 drug candidates in MYLAN's (VTRS) pipeline across Phase 3, Phase 2. Its lead program is MR-107A-02 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is MYLAN's next FDA catalyst?→
MYLAN's (VTRS) next tracked catalyst is a PDUFA date expected Dec 27, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track VTRS biotech catalysts?→
Add VTRS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow MYLAN's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.